Lipella Reveals Receipt Of FDA Type-C Meeting Guidance Regarding LP-10 (Liposomal Tacrolimus) Clinical Program; Plans To Advance Lead Product Candidate To Phase 2b
Portfolio Pulse from Benzinga Newsdesk
Lipella Pharmaceuticals has received FDA Type-C meeting guidance for its LP-10 (Liposomal Tacrolimus) clinical program and plans to advance its lead product candidate to Phase 2b. The trial will evaluate LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024.
May 21, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lipella Pharmaceuticals has received FDA guidance for its LP-10 clinical program and plans to advance to a Phase 2b trial in 2024. This regulatory clarity is a positive development for the company.
The receipt of FDA guidance and the plan to advance to a Phase 2b trial are significant milestones for Lipella Pharmaceuticals. This regulatory clarity boosts investor confidence and enhances the company's value proposition.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100